| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Vericiguat (JAN/USAN/INN); Verquvo (TN) | ||||||
| Product | VERQUVO (Merck Sharp & Dohme LLC) | ||||||
| Formula | C19H16F2N8O2 | ||||||
| Exact mass | 426.1364 | ||||||
| Mol weight | 426.3795 | ||||||
| Structure |  | ||||||
| Simcomp | |||||||
| Class | Cardiovascular agent DG03006 Guanylate cyclase activator Metabolizing enzyme substrate DG02924 UGT substrate DG03183 UGT1A1 substrate DG03188 UGT1A9 substrate | ||||||
| Remark |
| ||||||
| Efficacy | Vasodilator, Guanylate cyclase activator | ||||||
| Target | GUCY1A [HSA:2977 2982] [KO:K12318] GUCY1B [HSA:2983] [KO:K12319] | ||||||
| Pathway |
| ||||||
| Metabolism | Enzyme: UGT1A9 [HSA:54600]; UGT1A1 [HSA:54658] | ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] C CARDIOVASCULAR SYSTEM C01 CARDIAC THERAPY C01D VASODILATORS USED IN CARDIAC DISEASES C01DX Other vasodilators used in cardiac diseases C01DX22 Vericiguat D11051 Vericiguat (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Cardiovascular Agents Vasodilators Guanylate Cyclase (sGC) Stimulators Vericiguat D11051 Vericiguat (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 21 Cardiovascular agents 219 Miscellaneous 2190 Miscellaneous D11051 Vericiguat (JAN/USAN/INN) Drug groups [BR:br08330] Cardiovascular agent DG03006 Guanylate cyclase activator D11051 Vericiguat Metabolizing enzyme substrate DG02924 UGT substrate DG03183 UGT1A1 substrate D11051 Vericiguat DG03188 UGT1A9 substrate D11051 Vericiguat Target-based classification of drugs [BR:br08310] Enzymes Lyases (EC4) Phosphorus-oxygen lyases GUCY1A D11051 Vericiguat (JAN/USAN/INN) <JP/US> GUCY1B D11051 Vericiguat (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D11051 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D11051 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D11051 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D11051 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D11051 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 31 1 N5x N 19.1549 -13.7534 2 C8y C 19.1549 -15.1568 3 N5x N 20.3477 -15.8584 4 C8y C 21.6106 -15.1568 5 C8y C 21.6106 -13.7534 6 C8y C 20.3477 -13.0519 7 N1a N 20.3477 -11.6485 8 N1b N 22.8034 -13.0519 9 N1a N 22.8034 -15.8584 10 C7a C 23.9962 -13.7534 11 O7a O 25.1890 -13.0519 12 O6a O 23.9962 -15.1568 13 C1a C 26.3818 -13.7534 14 C8y C 17.9621 -15.8584 15 N4y N 15.7169 -15.9285 16 C8y C 16.1378 -17.1915 17 C8y C 17.5411 -17.1915 18 N5x N 16.8395 -15.0165 19 N5x N 15.5064 -18.4545 20 C8x C 16.2080 -19.6473 21 C8y C 17.6112 -19.6473 22 C8x C 18.3129 -18.3843 23 C1b C 14.5241 -15.2269 24 C8y C 13.3312 -15.9285 25 C8x C 12.1384 -15.2269 26 C8x C 10.8755 -15.9285 27 C8x C 10.8755 -17.3319 28 C8x C 12.0683 -18.0334 29 C8y C 13.3312 -17.3319 30 X F 14.5241 -18.0334 31 X F 18.3013 -20.8204 BOND 34 1 1 2 1 2 2 3 2 3 3 4 1 4 4 5 2 5 5 6 1 6 1 6 2 7 6 7 1 8 5 8 1 9 4 9 1 10 8 10 1 11 10 11 1 12 10 12 2 13 11 13 1 14 2 14 1 15 15 16 1 16 16 17 2 17 17 14 1 18 14 18 2 19 15 18 1 20 16 19 1 21 19 20 2 22 20 21 1 23 21 22 2 24 17 22 1 25 23 15 1 26 23 24 1 27 24 25 1 28 25 26 2 29 26 27 1 30 27 28 2 31 28 29 1 32 24 29 2 33 29 30 1 34 21 31 1 |